Breast Cancer: Targets and Therapy (Oct 2019)

Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients

  • Motamedi M,
  • Hashemzadeh Chaleshtori M,
  • Ghasemi S,
  • Mokarian F

Journal volume & issue
Vol. Volume 11
pp. 293 – 301

Abstract

Read online

Maryam Motamedi,1 Morteza Hashemzadeh Chaleshtori,1 Sorayya Ghasemi,1 Fariborz Mokarian2 1Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; 2Department of Hematology and Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IranCorrespondence: Sorayya GhasemiCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranTel/fax +98 38 33331471Email [email protected]: MiR-21 and miR-451 are closely associated with tumor initiation, drug resistance, and recurrence of breast cancer (BC). This study was conducted to evaluate the possible value of the plasma level of miR-21 and miR-451 as potential biomarkers for the detection of primary and recurrent BC.Patients and methods: In this descriptive–analytical study, the plasma level of miR-21 and miR-451 was measured in 23 primary BC patients, 24 recurrent (local/distant metastasis) BC patients, and 24 aged-match women as healthy controls using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Finally, data were analyzed using SPSS software, and the area under the receiver operating characteristic (ROC) curve of miRNAs was measured.Results: The plasma level of miR-21 was significantly increased in both groups of primary (P<0.001) and recurrent (P<0.001) BC patients in comparison with healthy women. However, the plasma level of miR-451 was not significantly changed in primary (P=0.065) and recurrent (P=0.06) BC patients than healthy controls. The elevation of both miR-21 and miR-451 plasma level was not significantly changed in recurrent patients compared with non-recurrent (primary) patients (P=0.481, and P=1, respectively). Based on the ROC analyses, the areas under the curves (AUC) for miR-21 in discriminating primary BC and recurrent BC patients from healthy controls were 0.828 (95% CI: 0.712 to 0.944) and 0.865 (95% CI: 0.756 to 0.974), respectively.Conclusion: These data indicating that plasma miR-21 may be useful as a biomarker for the detection of both primary and recurrent BC. However, plasma miR-451 lacks enough sensitivity in the detection of primary and recurrent BC, and more studies are needed in this area.Keywords: miRNA-21, miRNA-451, breast cancer, biomarker

Keywords